Ovarian Neoplasms: Clinical Trials

1,148 trials for Ovarian Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

532 completed, 199 terminated, 180 recruiting, 89 active not recruiting. 1148 Phase 1, 364 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11148Completed 532, Terminated 199, Recruiting 180, Active not recruiting 89, Unknown 73, Withdrawn 46, Not yet recruiting 20, Suspended 8, Enrolling by invitation 1
Phase 2364Completed 126, Terminated 77, Recruiting 75, Active not recruiting 30, Unknown 27, Withdrawn 18, Not yet recruiting 9, Enrolling by invitation 1, Suspended 1

Follow Ovarian Neoplasms: new trials by email Literature Review of Ovarian Neoplasms trials Research Report on Ovarian Neoplasms

Trials (filtered) newest first · largest first

All 1,148 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
LG00313112 - Ovarian Cancer, Small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingLG Chem2502026-12-012026-08-07
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
LY4336619, Sofetabart Mipitecan (Sofe-M) - Endometrial Neoplasms, Ovarian Neoplasms
Phase 1Not yet recruitingEli Lilly and Company3702026-12-012026-11-10
Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors
QLS5133; Lenvatinib mesylate, QLS5133; QL2107; Lenvatinib mesylate, QLS5133; Bevacizumab - Clear Cell Renal Cell Carcinoma, Ovarian Cancer
Phase 1 / Phase 2Not yet recruitingQilu Pharmaceutical Co., Ltd.5582026-11-152026-11-12
A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)
MK-6255, CD8 PET Tracer, Acetaminophen - Ovarian Neoplasms, Endometrial Neoplasms
Phase 1Not yet recruitingMerck Sharp & Dohme LLC802026-11-132026-11-16
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
CryptiVax-1001 - Ovarian Cancer, HGSOC
Phase 1RecruitingEpitopea Ltd502026-11-052026-11-10
Phase 1 Study of VT-101 in Advanced Ovarian Cancer
VT-101 - Epithelial Ovarian Cancer, Ovarian Cancer
Phase 1RecruitingMichael J. Goodheart222026-10-262026-11-09
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
CR-002 - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ
Phase 1 / Phase 2RecruitingCrescent Biopharma, Inc.2192026-10-212026-11-02
A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors.
YF550 - Solid Tumor (Phase I), Ovarian Cancer
Phase 1Not yet recruitingInventisBio Yiqi Beijing Limited2042026-10-012026-10-26
A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
TJ102 - Ovarian Cancer
Phase 1 / Phase 2RecruitingPhrontline Biopharma1502026-09-292026-11-12
Evaluation of XYA02 in Patients With Advanced Solid Tumors
XYA02 - MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingXYone Therapeutics, Inc1902026-09-172026-09-25
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
ABBV-253 - Advanced Solid Tumors, Non-Small Cell Lung Cancer
Phase 1RecruitingAbbVie1302026-09-142026-10-16
A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery
Low Dose, middle dose, high dose - Ovarian Cancer, mRNA Vaccine
Phase 1RecruitingWest China Hospital92026-09-102026-09-09
A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery
Low Dose NeoOVIV, Medium dose NeoOVIV, High dose NeoOVIV - Ovarian Cancer, mRNA Vaccine
Phase 1RecruitingWest China Hospital92026-09-102026-09-09
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII - Ovarian Cancer, Advanced Malignant Solid Tumor
Phase 1 / Phase 2RecruitingUniversity of Chicago242026-09-092026-10-13
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
TS-104 - NSCLC (Non-small Cell Lung Cancer), HNSCC
Phase 1RecruitingTwoStep Therapeutics, Inc.742026-09-022026-09-30
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
Sacituzumab govitecan monotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers
Phase 1RecruitingShanghai Gynecologic Oncology Group192026-09-022026-11-19
Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors
111In-TJD-31 Injection - Solid Tumors, Carcinoma
Phase 1Not yet recruitingYong He82026-09-012026-09-11
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms
Phase 1 / Phase 2Not yet recruitingAdvenchen Pharmaceuticals, LLC.1382026-09-012026-09-10
A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors
SI-B037 - Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors
Phase 1RecruitingSystImmune Inc.4002026-08-242026-11-17
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
GB-5267 - IV only, GB-5267 -Combined IV and IP Infusion - Platinum-resistant Ovarian Cancer
Phase 1RecruitingRoswell Park Cancer Institute332026-08-182026-10-22

Showing 20 of 1148. Sign in to see all of them.

Narrower conditions

Breast Neoplasms (326)  ·  Carcinoma, Non-Small-Cell Lung (253)  ·  Carcinoma, Ovarian Epithelial (249)  ·  Fallopian Tube Neoplasms (248)  ·  Endometrial Neoplasms (204)  ·  Colorectal Neoplasms (191)  ·  Pancreatic Neoplasms (188)  ·  Stomach Neoplasms (170)  ·  Neoplasms (159)  ·  Uterine Cervical Neoplasms (142)  ·  Prostatic Neoplasms (134)  ·  Melanoma (133)  ·  Lung Neoplasms (132)  ·  Triple Negative Breast Neoplasms (130)

Broader conditions

Female Urogenital Diseases (1148)  ·  Female Urogenital Diseases and Pregnancy Complications (1148)  ·  Genital Diseases (1148)  ·  Urogenital Diseases (1148)  ·  Endocrine System Diseases (1147)  ·  Genital Diseases, Female (1147)  ·  Gonadal Disorders (1147)  ·  Adnexal Diseases (1146)  ·  Endocrine Gland Neoplasms (1145)  ·  Urogenital Neoplasms (1143)  ·  Genital Neoplasms, Female (1141)  ·  Ovarian Diseases (1141)  ·  Neoplasms by Site (1140)  ·  Neoplasms (989)  ·  Neoplasms by Histologic Type (600)

Interventions

Carboplatin (132)  ·  Paclitaxel (121)  ·  pembrolizumab (68)  ·  Cyclophosphamide (61)  ·  Bevacizumab (52)  ·  Cisplatin (42)  ·  liposomal doxorubicin (41)  ·  Gemcitabine (40)  ·  Topotecan (34)  ·  Nivolumab (32)  ·  Taxes (30)  ·  olaparib (29)  ·  fludarabine (28)  ·  Docetaxel (23)  ·  Filgrastim (22)

Sponsors

National Cancer Institute (NCI) (73)  ·  M.D. Anderson Cancer Center (27)  ·  Memorial Sloan Kettering Cancer Center (20)  ·  AstraZeneca (19)  ·  Pfizer (17)  ·  Gynecologic Oncology Group (14)  ·  AbbVie (12)  ·  Eli Lilly and Company (12)  ·  Roswell Park Cancer Institute (12)  ·  City of Hope Medical Center (11)  ·  Ludwig Institute for Cancer Research (10)  ·  Masonic Cancer Center, University of Minnesota (10)  ·  Dana-Farber Cancer Institute (9)  ·  Incyte Corporation (9)  ·  University of Washington (9)

Countries

United States (824)  ·  China (115)  ·  Spain (105)  ·  United Kingdom (95)  ·  Australia (87)  ·  Canada (86)  ·  France (70)  ·  Belgium (57)  ·  Japan (47)  ·  South Korea (47)  ·  Netherlands (45)  ·  Italy (40)  ·  Germany (39)  ·  Switzerland (26)  ·  Denmark (23)

Top investigators

Paul Sabbatini, MD (7)  ·  Kunle Odunsi (6)  ·  Revolution Medicines, Inc. (4)  ·  Amir A Jazaeri (3)

Results publications

PMID 40132910, PMID 16394300, PMID 19949018, PMID 22002018, PMID 29995186, PMID 32379297, PMID 34904813, PMID 35537408, PMID 36459691, PMID 36608308, PMID 37496366, PMID 38885312, PMID 40443562, PMID 41044356, PMID 11181662, PMID 11410496, PMID 11705489, PMID 12082455, PMID 12082456, PMID 12114401, PMID 12528778, PMID 12957454, PMID 14751144, PMID 14767498, PMID 15010069, PMID 15033677, PMID 15131031, PMID 15592836, PMID 16135465, PMID 16150481, PMID 16234526, PMID 16368439, PMID 16412499, PMID 16626792, PMID 16631245, PMID 16914576, PMID 16959305, PMID 17194908, PMID 17910981, PMID 18191187, PMID 18245546, PMID 18281544, PMID 18327587, PMID 18451240, PMID 18483372, PMID 18692224, PMID 18974373, PMID 19075272, PMID 19088049, PMID 19192962

NIH funding

2023 (16), 2018 (12), U10CA027469 (12), 2017 (9), 2016 (7), 2025 (7), P30CA016056 (7), P30CA033572 (7), 2014 (6), 2015 (6), 2019 (6), UM1CA186709 (6), U10CA180868 (5), P30CA015083 (4), P30CA016672 (4)